Treatment of anxiety with ketazolam in elderly patients

N. Bresolin, G. Monza, E. Scarpini, G. Scarlato, G. Straneo, A. Martinazzoli, G. Beninca, C. Cattoni, R. De Candia, G. Belloni, M. Poggio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. At the end of this period, if their total scores on the Hamilton Anxiety Rating Scale had decreased by at least 25%, treatment was continued unchanged for a further 15 days. Patients who did not respond to treatment were given an additional 15 mg of ketazolam daily. During the initial 15 days, 83% of the ketazolam-treated patients and 43% of the placebo patients responded to treatment (P <0.01). During the second 15-day period, the anxiety scores of the ketazolam-treated patients continued to decline significantly, whereas the placebo patients showed no improvement. According to the investigators' assessments of severity of anxiety and patients' ratings of treatment effectiveness, ketazolam was significantly superior to placebo.

Original languageEnglish
Pages (from-to)536-542
Number of pages7
JournalClinical Therapeutics
Volume10
Issue number5
Publication statusPublished - 1988

Fingerprint

Anxiety
Placebos
Therapeutics
ketazolam
Anxiety Disorders
Research Personnel

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bresolin, N., Monza, G., Scarpini, E., Scarlato, G., Straneo, G., Martinazzoli, A., ... Poggio, M. (1988). Treatment of anxiety with ketazolam in elderly patients. Clinical Therapeutics, 10(5), 536-542.

Treatment of anxiety with ketazolam in elderly patients. / Bresolin, N.; Monza, G.; Scarpini, E.; Scarlato, G.; Straneo, G.; Martinazzoli, A.; Beninca, G.; Cattoni, C.; De Candia, R.; Belloni, G.; Poggio, M.

In: Clinical Therapeutics, Vol. 10, No. 5, 1988, p. 536-542.

Research output: Contribution to journalArticle

Bresolin, N, Monza, G, Scarpini, E, Scarlato, G, Straneo, G, Martinazzoli, A, Beninca, G, Cattoni, C, De Candia, R, Belloni, G & Poggio, M 1988, 'Treatment of anxiety with ketazolam in elderly patients', Clinical Therapeutics, vol. 10, no. 5, pp. 536-542.
Bresolin N, Monza G, Scarpini E, Scarlato G, Straneo G, Martinazzoli A et al. Treatment of anxiety with ketazolam in elderly patients. Clinical Therapeutics. 1988;10(5):536-542.
Bresolin, N. ; Monza, G. ; Scarpini, E. ; Scarlato, G. ; Straneo, G. ; Martinazzoli, A. ; Beninca, G. ; Cattoni, C. ; De Candia, R. ; Belloni, G. ; Poggio, M. / Treatment of anxiety with ketazolam in elderly patients. In: Clinical Therapeutics. 1988 ; Vol. 10, No. 5. pp. 536-542.
@article{2c1016d4930d40f8b712d13265be087c,
title = "Treatment of anxiety with ketazolam in elderly patients",
abstract = "In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. At the end of this period, if their total scores on the Hamilton Anxiety Rating Scale had decreased by at least 25{\%}, treatment was continued unchanged for a further 15 days. Patients who did not respond to treatment were given an additional 15 mg of ketazolam daily. During the initial 15 days, 83{\%} of the ketazolam-treated patients and 43{\%} of the placebo patients responded to treatment (P <0.01). During the second 15-day period, the anxiety scores of the ketazolam-treated patients continued to decline significantly, whereas the placebo patients showed no improvement. According to the investigators' assessments of severity of anxiety and patients' ratings of treatment effectiveness, ketazolam was significantly superior to placebo.",
author = "N. Bresolin and G. Monza and E. Scarpini and G. Scarlato and G. Straneo and A. Martinazzoli and G. Beninca and C. Cattoni and {De Candia}, R. and G. Belloni and M. Poggio",
year = "1988",
language = "English",
volume = "10",
pages = "536--542",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of anxiety with ketazolam in elderly patients

AU - Bresolin, N.

AU - Monza, G.

AU - Scarpini, E.

AU - Scarlato, G.

AU - Straneo, G.

AU - Martinazzoli, A.

AU - Beninca, G.

AU - Cattoni, C.

AU - De Candia, R.

AU - Belloni, G.

AU - Poggio, M.

PY - 1988

Y1 - 1988

N2 - In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. At the end of this period, if their total scores on the Hamilton Anxiety Rating Scale had decreased by at least 25%, treatment was continued unchanged for a further 15 days. Patients who did not respond to treatment were given an additional 15 mg of ketazolam daily. During the initial 15 days, 83% of the ketazolam-treated patients and 43% of the placebo patients responded to treatment (P <0.01). During the second 15-day period, the anxiety scores of the ketazolam-treated patients continued to decline significantly, whereas the placebo patients showed no improvement. According to the investigators' assessments of severity of anxiety and patients' ratings of treatment effectiveness, ketazolam was significantly superior to placebo.

AB - In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. At the end of this period, if their total scores on the Hamilton Anxiety Rating Scale had decreased by at least 25%, treatment was continued unchanged for a further 15 days. Patients who did not respond to treatment were given an additional 15 mg of ketazolam daily. During the initial 15 days, 83% of the ketazolam-treated patients and 43% of the placebo patients responded to treatment (P <0.01). During the second 15-day period, the anxiety scores of the ketazolam-treated patients continued to decline significantly, whereas the placebo patients showed no improvement. According to the investigators' assessments of severity of anxiety and patients' ratings of treatment effectiveness, ketazolam was significantly superior to placebo.

UR - http://www.scopus.com/inward/record.url?scp=0023713764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023713764&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 536

EP - 542

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 5

ER -